Ullrich Evelyn, Ménard Cédric, Flament Caroline, Terme Magali, Mignot Grégoire, Bonmort Mathieu, Plumas Jöel, Chaperot Laurence, Chaput Nathalie, Zitvogel Laurence
Institut Gustave Roussy, Villejuif, France.
Cytokine Growth Factor Rev. 2008 Feb;19(1):79-92. doi: 10.1016/j.cytogfr.2007.10.009. Epub 2007 Dec 26.
Tumor growth results from a delicate balance between intrinsic dysregulation of oncogenes, tumor suppressor and stability genes counteracted by extrinsic defenses composed of immune cells shaping tumor immunogenicity. Although immune subversion might be the ultimate outcome of this process, a complex network of cellular interactions take place eventually leading to tumor specific cognate immune responses. The links between innate and cognate antitumor immunity eliciting protective T cell responses are instigated by cytokines, chemokines and damage associated molecular patterns. The intricate differentiation pathway whereby dendritic cells could undergo an efficient maturation program in the tumor microenvironment appears crucial. We will discuss the role of innate effectors and cancer therapies in the process of defense against tumor cells.
肿瘤生长源于癌基因、肿瘤抑制基因和稳定性基因的内在失调与由塑造肿瘤免疫原性的免疫细胞组成的外在防御之间的微妙平衡。尽管免疫颠覆可能是这一过程的最终结果，但最终会发生一个复杂的细胞相互作用网络，导致肿瘤特异性同源免疫反应。引发保护性T细胞反应的固有免疫和同源抗肿瘤免疫之间的联系是由细胞因子、趋化因子和损伤相关分子模式激发的。树突状细胞在肿瘤微环境中能够经历高效成熟程序的复杂分化途径似乎至关重要。我们将讨论固有效应器和癌症治疗在抵御肿瘤细胞过程中的作用。
